The Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC) and Innovate Manchester Advanced Therapy Centre Hub (iMATCH) have collaborated to produce a new clinical scenario video intended to support training in the management of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T cell therapy.

Immune effector cell (IEC) therapies are used to modulate an immune response for therapeutic intent. Currently, CAR T cell therapy is the most commonly used type of IEC therapy, offering transformative options for patients with certain haematological malignancies. Many CAR T products and other IEC therapies are in development for a wide range of indications including blood cancers and solid tumours.

Despite their clinical success, the use of IEC therapies can result in significant toxicities that are directly associated with powerful immune-mediated responses. The most frequently observed such toxicity is cytokine release syndrome. CRS represents a life-​threatening situation that requires early recognition of symptoms and signs and prompt intervention. This short training video can be used to support healthcare professionals and others to gain an introduction to CRS presentation, diagnosis and clinical management.

The 8-minute video was produced with input from NHS Blood and Transplant, The Christie NHS Foundation Trust, Cardiff and Vale University Health Board, Bristol and Weston Hospitals NHS Foundation Trust and University Hospitals Birmingham NHS Foundation Trust, and references guidance produced by the UK Pharmacy Working Group for ATMPs.

The video can be accessed via the Education and Training Resources section of the NHS Readiness Toolkit on the ATTC website, which you can visit here: